Entheon Biomedical Corp.: Entheon Biomedical Lists on OTCQB Venture Market
Entheon or the
Company ), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has been approved for trading on the OTCQB Venture Market ( OTCQB ) effective May 5, 2021. We are thrilled to be up-listing on to the OTCQB, which will allow for greater engagement with our U.S. investor base. As we advance our DMT addiction therapy program toward human trials, continue R&D on our diagnostic and patient-monitoring platform, and scale up commercial availability of our subsidiary, HaluGen Life Science s Psychedelics Genetic Test, we are pleased to be gaining increased visibility and investor access within the U.S. market, said Timothy Ko, CEO of Entheon.
Entheon Biomedical Lists on OTCQB Venture Market streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Kyowa Kirin North America, the Bedminster-based unit of Japan’s Kyowa Kirin Co. Ltd., said this week that it is continuing its business integration initiative, merging a pair of units to streamline its structure.
The pharmaceutical company said in a news release that it is merging its Kyowa Kirin Research and Kyowa Kirin Development companies into one business, called Kyowa Kirin Inc., as part of its ongoing North American Business Integration, or NABI, initiative.
The goal of the initiative is a simpler business structure and common set of processes and systems.
“The organizational changes we are making through NABI will help Kyowa Kirin North America deliver the full value of these (pipeline) opportunities,” Gary Zieziula, president of KKNA, said in a prepared statement. “Through NABI, we’re working to enable more efficient collaborations and business support for the functions that discover, develop and deliver first-in-class medicines that can have a profound impact o
(2)
Senior Pharmaceutical & Technology Executive and Current SVP, Chief Information Officer, North America at Kyowa Kirin International plc., Previously of IBM, Schering-Plough, Merck and Gilead Joins Entheon s Advisory Board
Vancouver, British Columbia (Newsfile Corp. - March 3, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (
Entheon or the
Company ), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce Nancy Maher as Special Advisor of Data Science and Regulatory Affairs, providing expertise on the development of the Company s data strategy design, study design and advise on regulatory relationships and data strategy.
Ms. Maher has served as an executive and consultant for major pharmaceutical and information technology companies, including IBM, Gilead, Schering-Plough, Merck, Allergan, and Teva Pharmaceuticals. Ms. Maher is currently SVP, Chief Information Officer, North America of Kyo